ANXA11 and ovarian carcinoma: ANXA3 was upregulated in platinum-resistant ovarian cancer [7], whereas ANXA1 and ANXA11 expression was negatively correlated with paclitaxel and cisplatin resistance in ovarian cancer, respectively [42, 43].